Certain individuals are more responsive to CAR T cell therapy than others. This could be due to heterogeneity in the CAR T infusion product or to a difference in the patient’s immune system. Researchers initially used flow cytometry or bulk RNA sequencing to characterize endogenous immune cells and therapeutic CAR T cells, but these approaches lack the resolving power needed to profile all immune cell types and states present in the population. The advent of single-cell transcriptomics has enabled scientists to deeply profile complex cell populations to refine the infusion product and tailor it to the patient.
Download this white paper from 10x Genomics to discover how targeted single-cell transcriptomics
- Analyzes transduction efficiency in individual therapeutic cells
- Detects and characterizes CAR T cell heterogeneity
- Connects a cell's transcriptome to its functional state
